• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment

Promising New Male Contraceptive Passes First Human Safety Trial : ScienceAlert todayheadline

July 31, 2025
in Science & Environment
Reading Time: 5 mins read
A A
0
man taking pill
2
SHARES
5
VIEWS
Share on FacebookShare on Twitter


A potential new male contraceptive drug has just undergone its first tests in human volunteers. The results give the first indication that the drug, which does not use artificial hormones or affect testosterone production by the testes, may be safe in humans.

While previous attempts have been made to develop a male contraceptive in the past, these largely failed to pass clinical trials due to their unacceptable side effects.

But this newest contraceptive works differently from past attempts, which means it doesn’t require surgery and is much less likely to cause hormonal side effects – problems that have helped stop previous attempts from reaching the market.

The study showed the drug was well tolerated in a small group of healthy young men and did not appear to cause any serious side effects at the doses used. Further research will be needed to demonstrate precisely how effective it is as a contraceptive.

Related: New Type of Reversible Male Contraception Proves a Success in Mouse Study

The new method uses a specially designed chemical known as YCT-529 to target a specific cell receptor in the testes called retinoic acid receptor–alpha.

Similar, but less specific compounds, had been shown to reduce sperm production in humans previously. But these compounds also had unwanted side effects – such as feeling ill when drinking alcohol, altering salt levels in the bloodstream and not being fully reversible in all men. This made them unsuitable for contraceptive use.

Previous attempts at a male contraceptive pill have proven unsuitable. (Ron Lach/Pexels/Canva)

But in animal studies, YCT-529 was shown to produce fully reversible, temporary infertility without any significant side effects. A study in mice also found that those who went on to father babies after stopping the drug produce normal, healthy offspring.

Based on these results, the drug then entered into phase 1 trials in humans. This is the first stage of human testing, where a small group of healthy volunteers are recruited to test safety, tolerability, and possible side effects.

This small trial involved 16 male volunteers who took the drug twice at increasing doses – either 10mg to 30mg or 90mg to 180mg. Some men took placebo pills for comparison.

The participants were monitored for 15 days for any effects on normal hormone levels, inflammation (signs of cell damage), kidney and liver function, abnormal heart rhythms, sexual desire and mood.

No changes were detected in the natural hormones in the body. There were also no lasting effects on liver and kidney function and no signs of cell damage. No dangerous abnormalities of heart rhythm were detected, and the participants reported no changes in mood or sexual desire.

However, participants only took two doses of the drug and were only followed up for 15 days. The authors say in the paper that a larger phase 2 trial is underway which will test the drug in a greater number of men.

This will then be followed by phase 3 trials in hundreds of men where the effectiveness, reversibility and side effects of longer term use of the drug will be assessed. These are the hurdles which have prevented other approaches from being made widely available.

Why past male contraceptives have failed

At present there are no commercially available contraceptive methods for men that are not only safe and effective at preventing pregnancy, but which also allow sperm production to be turned off and on again at will.

While condoms have few side effects and are used at will, they have a relatively high failure rate (resulting in pregnancy around 12%-18% of the time with typical use).

A vasectomy, which severs the tube connecting the sperm-producing testes to the rest of the male reproductive organs, is very effective (more than 99%) and safe – but it’s not easily reversible and requires a minor operation.

vasectomy diagram
Diagram of a vasectomy. (Anna Bergbauer/Getty Images)

There have been previous attempts (and some ongoing) at producing a reversible method of contraception for men. Some have proven to be effective at stopping sperm production or preventing sperm from exiting the male reproductive tract. However, they haven’t moved to the stage of commercial production, often because of unwanted side effects.

Most of these attempts used one of two main approaches to prevent pregnancy.

One method involves injecting a substance into the vas deferens (a tube leading from the testes to the urethra). This substance filters out and damages sperm during ejaculation. This substance can be flushed out through a minor procedure if the man wishes to become fertile again.

The drawback of this method is that it requires a minor surgical procedure (an injection into the scrotum) and that the man has to have a further procedure to reverse its effects.

The second route involves stopping sperm production altogether by lowering the hormones that cause sperm to be made in the testes.

The most successful of these trials used an injectable progestogen (a synthetic version of the sex hormone progesterone). This injectable signalled the brain to stop producing follicular-stimulating hormone (FSH) and lutenising hormone (LH), which normally signal the testes to produce sperm and testosterone.

However, suppressing LH also turned off the testosterone in the testes that is needed for normal, healthy function in men. To counteract the loss of testosterone, this contraceptive approach required men to take an “add back” testosterone – either as a tablet or a gel applied to the skin.

But a major trial testing this method was stopped early because of the hormonal side effects participants experienced, including mood swings, acne and changes to sex drive.

There’s a long way to go before the new drug can be considered suitable for use as a male contraceptive. But this new approach shows a lot of promise because it avoids upsetting hormonal balance and can be taken orally – rather than requiring an invasive procedure. The Conversation

Susan Walker, Associate Professor in Contraception, Reproductive and Sexual Health, Anglia Ruskin University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Previous Post

NASA Installs Key ‘Sunblock’ Shield on Roman Space Telescope

Next Post

Sri Lanka opens US$1.2bn of vehicle import LCs : President todayheadline

Related Posts

Four glowing black spheres against a black smoky background

Did ‘primordial’ black holes born right after the Big Bang help our universe’s 1st stars form?

August 1, 2025
8
Lifestyle interventions reshape gene regulation in skeletal muscle of Asians

Lifestyle interventions reshape gene regulation in skeletal muscle of Asians

August 1, 2025
6
Next Post

Sri Lanka opens US$1.2bn of vehicle import LCs : President todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

Waystar (WAY) Q2 Revenue Jumps 15% todayheadline

August 1, 2025

Avient Corp earnings beat by $0.01, revenue topped estimates todayheadline

August 1, 2025
Four glowing black spheres against a black smoky background

Did ‘primordial’ black holes born right after the Big Bang help our universe’s 1st stars form?

August 1, 2025
Lifestyle interventions reshape gene regulation in skeletal muscle of Asians

Lifestyle interventions reshape gene regulation in skeletal muscle of Asians

August 1, 2025

Recent News

Waystar (WAY) Q2 Revenue Jumps 15% todayheadline

August 1, 2025
5

Avient Corp earnings beat by $0.01, revenue topped estimates todayheadline

August 1, 2025
7
Four glowing black spheres against a black smoky background

Did ‘primordial’ black holes born right after the Big Bang help our universe’s 1st stars form?

August 1, 2025
8
Lifestyle interventions reshape gene regulation in skeletal muscle of Asians

Lifestyle interventions reshape gene regulation in skeletal muscle of Asians

August 1, 2025
6

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Waystar (WAY) Q2 Revenue Jumps 15% todayheadline

August 1, 2025

Avient Corp earnings beat by $0.01, revenue topped estimates todayheadline

August 1, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co